Intravitreal Injection of Triamcinolone acetonide suspensions for Low Viscosity, highly flocculated

摘要

Claim 1: an aqueous suspension composition particularly suitable for injection into the eye, where the suspension composition contains no Preservative, has a pH of 6 to 7.5, a viscosity of 2 - 12 cps, and a greater degree of Flocculation and 5, in which the composition of suspen Zion consisting essentially of: (a) 3.5 - 45% (W / V) Triamcinolone acetonide has a volume mean diameter of 3 - 10 mm; (b) 0,45 and 0,55% (W / V) Sodium CarboxyMethyl Cellulose; (c) 0002 - 0,02% (W / V) Polysorbate 80; (d) one or more pharmaceutically acceptable salts chloride as agents to adjust the tone in an amount sufficient to cause suspension composition possesses osmolarity 250 - 350 mOsm); and a buffering agent; Water for injection; and (f) (g) optionally a pH adjusting Agent to adjust the pH Up to 7.5.Claim 1: suspension Composition of claim 1, wherein the suspension composition comprising Sodium Chloride, potassium chloride, Calcium chloride and magnesium chloride. Claim 1: suspension Composition of claim 1, wherein the Buffering Agent comprises SODIUM ACETATE and sodium Citrate.Claim 1: an aqueous suspension composition particularly suitable for injection into the eye, where the suspension composition contains no Preservative, has a pH of 6 - 8, a viscosity of 2 - 12 cps, and a greater degree of Flocculation and 5, in which the composition of suspension Nsion consists essentially of: (a) 0.5 to 8.0% (W / V) of a poorly soluble Drug,Where the drug has a volume average diameter of 3 - 10 mm; (b) 0,45 and 0,55% (W / V) Sodium CarboxyMethyl Cellulose; (c) 0002 - 0.02% (W / V) Polysorbate 80 or tyloxapol; (d) one or more pharmaceutically acceptable salts of chloride as agents in accordance with the Tone; Water for injection On; (f) an optional buffering Agent,G) and optionally a pH adjusting Agent to adjust the pH to 6 - 8.Claim 1: suspension Composition of claim 14.Where the poorly soluble Drugs selected from the group consisting of drugs for the treatment of macular edema; Drugs for the treatment of retinal Vein Occlusion; drug for the treatment of Geographic atrophy; Drugs for the treatment of Dry Macular Degeneration related With age; and Drugs for the treatment of Wet Macular Degeneration related to EDAD. claim 16: suspension Composition of claim 1, wherein the tandospirone is poorly soluble drugs.